Advertisement

Frailty and Hormones

  • John E. MorleyEmail author
  • Moon Jong Kim
  • Matthew T. Haren
Article

Key words

frailty testosterone myostatin muscle 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol Med Sci 2004;59A:255–263.Google Scholar
  2. 2.
    Morley JE, Perry HM, Miller DK. Something about frailty. J Gerontol Med Sci 2002;57A:M698–M704.Google Scholar
  3. 3.
    Brown I, Renwick R, Raphael D. Frailty: constructing a common meaning, definition, and conceptual framework. Int J Rehab Res 1995;18:93–102.Google Scholar
  4. 4.
    Hougaard P. Frailty models for survival data. Lifetime Data Analysis 1995;1:255–273.Google Scholar
  5. 5.
    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: Evidence for a phenotype. J Gerontol Med Sci2001;56A:M146–156.Google Scholar
  6. 6.
    Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410–413.Google Scholar
  7. 7.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724-731.Google Scholar
  8. 8.
    Morley JE, Patrick P, Perry HM. Evaluation of assays available to measure free testosterone. Metab Clin Exper 2002;51:554-559.Google Scholar
  9. 9.
    Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mechanisms of Ageing & Development 1999;107:123–136.Google Scholar
  10. 10.
    Matsumoto AM. Andropause: clinical Implication of the Decline in Serum Testosterone Levels with Aging in Men. J Gerontol Med Sci 2002;57A:M76–M99.Google Scholar
  11. 11.
    Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Molec Biol2003;85:367–373.Google Scholar
  12. 12.
    Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Med Sci 2003;58A:618–625.Google Scholar
  13. 13.
    Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci2001;56A:M266–M272.Google Scholar
  14. 14.
    Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647–2653.Google Scholar
  15. 15.
    Morley JE, Perry HM III, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149–152.Google Scholar
  16. 16.
    Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men—a 12-month randomized controlled trial. J Clin Endocrin Metab 1997;82:1661–1667.Google Scholar
  17. 17.
    Haren MT, Morley JE, Chapman IM, O’Loughlin PD, Wittert GA. Defining ‘relative’ androgen deficiency in aging men: How should testosterone be measured and what are the relationship between androgen levels and physical, sexual and emotional health? Climacteric 2002;5:15–25.Google Scholar
  18. 18.
    Flood JF, Farr SA, Kaiser FE, Laregina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice—replacement improves age-related impairment of learning and memory.Physiology & Behavior 1995;57:669–673.Google Scholar
  19. 19.
    Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S. Testosterone supplementation improves spatial and verbal memory in health older men. Neurology 2001;57:80–88.Google Scholar
  20. 20.
    Kenny AM, Fabregas G, Song CW, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. Gerontol Med Sci2004;59A:75–78.Google Scholar
  21. 21.
    Perry HM, Miller Dk, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metab Clin Exper 2000;49:1085–1091.Google Scholar
  22. 22.
    Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men.J Am Geriatr Soc 2000;48:550–553.Google Scholar
  23. 23.
    Amory JK, Chansky HA, Chansky KL, Camuso MR, Hoey CT,Anawalt BD, Matsumoto AM, Bremner WJ. Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc 2002;50:1698–1701.Google Scholar
  24. 24.
    Morley JE, Kaiser FE, Sih R, Hajjar R, Perry HM. Testosterone and frailty. Clin Geriatr Med 1997;13:685ff.Google Scholar
  25. 25.
    Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol Med Sci 2003;58A:1002–1008.Google Scholar
  26. 26.
    Morley JE, Perry HM III. Androgens and women at the menopause and beyond. J Gerontol Med Sci 2003;58:M409–M416.Google Scholar
  27. 27.
    Morley JE. Is the hormonal fountain of youth drying up? J Gerontol Med Sci 2004;59A:458–460.Google Scholar
  28. 28.
    Valenti G, Denti L, Maggio M, Ceda G, Volpato S, Bandinelli S, Ceresini G, Cappola A, Guralnik JM Ferrucci L. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol Med Sci 2004;59A:466–472.Google Scholar
  29. 29.
    Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SSC. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.Clin Endocrinol 1998;49:421–432.Google Scholar
  30. 30.
    Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Nat Acad Sci USA 2000;97:4279–4284.Google Scholar
  31. 31.
    Percheren G, Hogrel JY, Denot-Ledunois S, fayet G, Forette F, Baulieu EE, Fardeau M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60-to 80-year-old individuals on muscle function and cross-sectional area—a double-blind placebo-controlled trial. Arch Int Med 2003;163:720–727.Google Scholar
  32. 32.
    Perry HM III, Horowitz M, Morley JE, Patrick P, Vellas B, Baumgartner R, Garry PJ. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metab Clin Exper 1999;48:1028–1032.Google Scholar
  33. 33.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med1992;327:1637–1642.Google Scholar
  34. 34.
    Larson ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Min Res 2004;19:370–378.Google Scholar
  35. 35.
    Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Molec Biol2004;89–90 F1–5 Special Issue SI):497–501.Google Scholar
  36. 36.
    Fletcher D. Neurologic disease, falls and fractures. J Neurol Sci 2004;223:101–102.Google Scholar
  37. 37.
    Zamboni M, Zoico E, Tosoni P, Zivelonghi A, Bortolani A, Maggi S, Di Francesco V, Bosello O. Relation between vitamin D, physical performance, and disability in elderly persons. J Gerontol Med Sci 2002;57A:M7–M11.Google Scholar
  38. 38.
    Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SHD, Swift CG, Allain TJ. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Min Res 2002;17:891–897.Google Scholar
  39. 39.
    Roth SM, Zmuda JM, Cauley JA, Shea PR, Ferrell RE. Vitamin D receptor genotype is associated with fat-free mass and sarcopenia in elderly men. J Gerontol Med Sci 2004;59A:10–15.Google Scholar
  40. 40.
    Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: A systematic review. J Am Geriatr Soc2003;51:1219–1226.Google Scholar
  41. 41.
    Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stahelin HB. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004;52:230–236.Google Scholar
  42. 42.
    Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of vitamin D on falls—a meta-analysis. JAMA 2004;291:1999–2006.Google Scholar
  43. 43.
    Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc 1985;33:800–807.Google Scholar
  44. 44.
    Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Hormone Research 2003;60(Suppl 1):121–124.Google Scholar
  45. 45.
    Horani MH, Morley JE. Hormonal fountains of youth. Clin Geriatr Med 2004;20:275–+.Google Scholar
  46. 46.
    Harman SM, Blackman MR. Use of growth hormone for prevention or treatment of effects of aging. J Gerontol Med Sci2004;59A:652–658.Google Scholar
  47. 47.
    Chu LW, Lam KSL, Tam SCF, Hu WJHC, Hui SL, Chiu A, Chiu KC, Ng P. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients.J Clin Endocrinol Metab 2001;86:1913–1920.Google Scholar
  48. 48.
    Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991;39:235–240.Google Scholar
  49. 49.
    McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiology-London 1999;516:583–592.Google Scholar
  50. 50.
    Grounds MD. Reasons for degeneration of ageing skeletal muscle: A central fole for IGF-1 signalling. Biogerontology2002;3:19–24.Google Scholar
  51. 51.
    Chakravarthy MV, Booth FW, Spangenburg EE, Booth FW. The molecular responses of skeletal muscle satellite cells to continuous expression of IGF-1: Implications for the rescue of induced muscular atrophy in aged rats. Int J Sport Nutr Exercise Metab 2001;11(Suppl):S44–S48.Google Scholar
  52. 52.
    Harridge SDR. Ageing and local growth factors in muscle.Scand J Med Sci Sports 2003;13:34–39.Google Scholar
  53. 53.
    Alzghoul MB, Gerrard D, Watkins BA, Hannon K. Ectopic expression of IGF-1 and SHH by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB Journal 2003;17:NIL495–NIL517.Google Scholar
  54. 54.
    Musaro A, McCullagh K, paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics 2001;27:195–200.Google Scholar
  55. 55.
    Mooradian AD, Wong NC. Age-related changes in thyroid hormone action. J Endocrinol 1994;131:451–461.Google Scholar
  56. 56.
    Morley JE. Hormones and the aging process. J Am Geriatr Soc 2003;51(7 Suppl S):S333–S337.Google Scholar
  57. 57.
    Banks WA, Morley JE. Endocrine and metabolic changes in human aging. J Am Aging Assoc 2000;23:103–115.Google Scholar
  58. 58.
    Morley JE. Diabetes mellitus: A major disease of older persons.J Gerontol Med Sci 2000;55A:M255–M256.Google Scholar
  59. 59.
    Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Diabetes as a predictor of change in functional status among older Mexican Americans—a population-based cohort study. Diabetes Care 2003;26A:314–319.Google Scholar
  60. 60.
    Blaum CS, Ofstedal MB, Langa KM, Wray LA. Functional status and health outcomes in older Americans with diabetes mellitus.J Am Geriatr Soc 2003;51:745–753.Google Scholar
  61. 61.
    Valderrama-Gama E, Damian J, Ruigomez A, Martin-Moreno JM. Chronic disease, functional status, and self-ascribed causes of disabilities among noninstitutionalize dolder people in Spain. J Gerontol Med Sci 2002;57A:M716–M721.Google Scholar
  62. 62.
    Maty SC, Fried LP, Volpato S, Williamson J, Brancati FL, Blaum CS. Patterns of disability related to diabetes mellitus in older women. J Gerontol Med Sci 2004;59A:148–153.Google Scholar
  63. 63.
    Rodriguez-Saldana J, Morley JE, Reynoso MT, Medina CA, Salazar P, Cruz E, Torres ALN. Diabetes mellitus in a subgroup of older Mexicans: Prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality.J Am Geriatr Soc 2002;50:111–116.Google Scholar
  64. 64.
    Miller DK, Lui LYL, Perry HM, Kaiser FE, Morley JE. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol Med Sci 1999;54A:M230-M236.Google Scholar
  65. 65.
    Sinclair AJ. Diabetes in the elderly—a perspective from the United Kingdom.Clin Geriatr Med 1999;15:225–+.Google Scholar
  66. 66.
    Brandon LJ, Gaasch DA, Boyette LW, Lloyd AM. Effects of long-term resistive training on mobility and strength in older adults with diabetes. J Gerontol Med Sci 2003;58A:740–745.Google Scholar
  67. 67.
    Morley JE. The elderly Type 2 diabetic patient: Special considerations. Diabetic Med 1998;15(12 Suppl 4):S41–S46.Google Scholar
  68. 68.
    Banks WA, Morley JE. Memories are made of this: Recent advances in understanding cognitive impairments and dementia. J Gerontol Med Sci 2003;58A:314–321.Google Scholar
  69. 69.
    Morley JE. The SAMP8 mouse: A model of Alzheimer disease?Biogerontology 2002;3:57–60.Google Scholar
  70. 70.
    Morley JE,Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF. Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 2000;21:1761–1767.Google Scholar
  71. 71.
    Bruce DG, Casey GP, Grange V, Clarnette RC, Almeida OP, Foster JK, Ives FJ, Davis TME. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: The Fremantle Cognition in Diabetes Study. Diab Res Clin Pract2003;61:59–67.Google Scholar
  72. 72.
    Flood JF, Mooradian AD, Morley JE. Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes1990;39:1391–1398.Google Scholar
  73. 73.
    Mooradian AD, Perryman K, Fitten J, Kavonian GD, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies. Arch Int Med 1988;148:2369–2372.Google Scholar
  74. 74.
    Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993;48:M117–M121.Google Scholar
  75. 75.
    Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, McClearn G, Johansson B. Type 2 diabetes mellitus contributes to cognitive decline in old age: A longitudinal population-based study. J Int Neuropsychol Soc 2004;10:599–607.Google Scholar
  76. 76.
    Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer’s disease: Review and hypothesis. J Gerontol Med Sci 2004;59A:178–183.Google Scholar
  77. 77.
    Morley JE. The metabolic syndrome and aging. J Gerontol Med Sci 2004;59A:139–142.Google Scholar
  78. 78.
    Vischer U, Szanto I, Michel JP. The association between insulin resistance, depression, and dementia. J Gerontol Med Sci2004;59A:189–191.Google Scholar
  79. 79.
    Chait A, Robertson HT, Brunzell JD. Chylomicronemia syndrome in diabetes mellitus. Diabetes Care 1981;4:343–348.Google Scholar
  80. 80.
    Rogers RL, Meyer JS, McClintic K, Mortel KF. Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology 1989;40(4 Pt 1):260–269.Google Scholar
  81. 81.
    Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004;53:1253–1260.Google Scholar
  82. 82.
    Shanley LJ, Irving AJ, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 2001;21:RC186.Google Scholar
  83. 83.
    Morley JE, Baumgartner RN. Cytokine-related aging process.J Gerontol Med Sci 2004;59A:924–929.Google Scholar
  84. 84.
    Ceccarelli E, Donati C, Forconi S, Masotti L. C-reactive protein, physical disability, and prognosis in very old patients with ischemic stroke. J Gerontol Med Sci 2002;57A:M520–M522.Google Scholar
  85. 85.
    Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur Studies of Successful Aging. J Gerontol Med Sci 2000;55A:M709–M715.Google Scholar
  86. 86.
    Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, Seeman TE. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 2002;50:638–644.Google Scholar
  87. 87.
    Banks WA, farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes.Neuroimmunomodulation 2002;10:319–327.Google Scholar
  88. 88.
    Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ann Rev Med2000;51:245–270.Google Scholar
  89. 89.
    Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Developmental & Comparative Immunology 1997;21:487–499.Google Scholar
  90. 90.
    Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1–7.Google Scholar
  91. 91.
    Nordstrom A, Gerdhem P, Brandstrom H, Stiger F, Lerner UH, Lorentzon M, Obrant K, Nordstrom P, Akesson K. Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women. Osteoporosis Int 2004;15:820–826.Google Scholar
  92. 92.
    Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001;8:131–136.Google Scholar
  93. 93.
    Blair HC, Athanasou NA. Recent advances in osteoclast biology and pathological bone resorption. Histology &Histopathology 2004;19:189–199.Google Scholar
  94. 94.
    Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 2004;15:49–60.Google Scholar
  95. 95.
    Kanazawa K, Azuma Y, Nakano H, Kudo A. TRAF5 functions in both RANKL- and TNF-alpha-induced osteoclastogenesis. J Bone Min Res 2003;18:443–450.Google Scholar
  96. 96.
    Kaji K, Katogi R, Azuma Y, Naito A, Inoue JI, Kudo A. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Min Res 2001;16:1593–1599.Google Scholar
  97. 97.
    Cesari M, Penninx BW, Lauretani F, Russo CR, Carter C, Bandinelli S, Atkinson H, Onder G, Pahor M, Ferrucci L. Hemoglobin levels and skeletal muscle: Results from the InCHIANTI study. J Gerontol Med Sci 2004;59A:249–254.Google Scholar
  98. 98.
    Thomas DR. Anemia and quality of life: Unrecognized and undertreated. J Gerontol Med Sci 2004;59A:238–241.Google Scholar
  99. 99.
    Visser M, Pahor M, Taaffee DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The health ABC study. J Gerontol Med Sci 2002;57A:M326–M332.Google Scholar
  100. 100.
    Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR, Guralnik JM, Ferrucci L. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol Med Sci 2004;59A:242–248.Google Scholar
  101. 101.
    Morley JE. Pathophysiology of anorexia. Clin Geriatr Med2002;18:661–673.Google Scholar
  102. 102.
    Silver AJ, Morley JE. Role of the opioid system in the hypodipsia associated with aging. J Am Geriatr Soc1992;40:556–560.Google Scholar
  103. 103.
    Miller M, Morley JE, Rubesntein LZ. Hyponatremia in a nursing home population. J Am Geriatr Soc 1995;43:1410–1413.Google Scholar
  104. 104.
    Chapman IM, MacIntosh CG, Morley JE, Horowitz M. The anorexia of ageing. Biogerontology 2002;3:67–71.Google Scholar
  105. 105.
    Morley JE. Anorexia of aging—physiologic and pathologic.Am J Clin Nutr 1997;66:760–773.Google Scholar
  106. 106.
    Clarkston WK, Pantano MM, Morley JE, Horowitz M, Littlefield JM, Burton FR. Evidence for the anorexia of aging—gastroinetestinal transit and hunger in healthy elderly vs young adults.Am J Physiol—Regulatory Integrative & Comparative Physiology 1997;41:R243–R248.Google Scholar
  107. 107.
    Rayner CK, MacIntosh CG, Chapman IM, Morley JE, Horowitz M. Effects of age on proximal gastric motor and sensory function. Scand J Gastroent 2000;35:1041–1047.Google Scholar
  108. 108.
    Sturm K, Parker B, Wishart J, Feinle-Bisset C, Jones KL, Chapman I, Horowitz M. Energy intake and appetite are related to antral area in healthy young and older subjects. Am J Clin Nutr 2004;80:656–667.Google Scholar
  109. 109.
    Sun WM, Doran S, Jones KL, Ooi E, Boeckxstaens G, Hebbard GS, Lingenfelser T, Morley JE, Dent J, Horowitz M. Effects of nitroglycerin on liquid gastric emptying and antropyloroduodenal motility. Am J Physiol 1998;275(5 Pt 1):G1173–G1178.Google Scholar
  110. 110.
    MacIntosh CG, Horowitz M, Verhagen MAMT, Smout AJMPM, Wishart J, Morris H, Goble E, Morley JE, Chapman IM. Effect of small intestinal nutrient infusion on appetite, gastrointestinal hormone release, and gastric myoelectrical activity in young and olde rmen. Am J Gastroenterol 2001;96:997–1007.Google Scholar
  111. 111.
    MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JBMJ, Horowitz M, Chapman IM. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: Evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001;86:5830–5837.Google Scholar
  112. 112.
    Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women.Mech Ageing Devel 1999;48:378–384.Google Scholar
  113. 113.
    Morley JE, Perry HM III, Baumgartner RP, Garry PJ. Leptin, adipose tissue and aging—is there a role for testosterone? J Gerontol Biol Sci 1999;54:B108–B109.Google Scholar
  114. 114.
    Morley JE, Alshaher MM, Farr SA, Flood JF, Kumar VB. Leptin and neuropeptide Y (NPY) modulate nitric oxide synthase: Further evidence for a role of nitric oxide in feeding. Peptides 1999;20:595–600.Google Scholar
  115. 115.
    Morley JE, Kumar VB, Mattammal MB, Farr S, Morley PM, Flood JF. Inhibition of feeding by a nitric oxide synthase inhibitor: Effects of aging. Euro J Pharmacol 1996;311:15–19.Google Scholar
  116. 116.
    Suda Y, Marske CE, Flaherty JH, Zdrodowski K, Morley JE. Examining the effect of intervention to nutritional problems of the elderly living in an inner city area: A pilot project. J Nutr Hlth Aging 2001;5:118–123.Google Scholar
  117. 117.
    Wilson MMG, Vaswani S, Liu D, Morley JE, Miller DK. Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998;104:56–63.Google Scholar
  118. 118.
    Morley JE, Kraenzle D. Causes of weight loss in a community nursing home. J Am Geriatr Soc 1994;42:583–585.Google Scholar
  119. 119.
    Blazer DB. Depression in late life: Review and commentary. J Gerontol Med Sci 2003;58A:249–265.Google Scholar
  120. 120.
    Tariq SH, Karcic E, Thomas DR, Thomson K, Philpot C, Chapel DL, Morley JE. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Dietetic Assoc 2001;101:1463–1466.Google Scholar
  121. 121.
    Morley JE, BaumgartnerRN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231–243.Google Scholar
  122. 122.
    Marcell TJ. Sarcopenia: Causes, consequences and preventions. J Gerontol Med Sci 2003;58A:911–916.Google Scholar
  123. 123.
    Morley JE. Anorexia, sarcopenia, and aging. Nutrition 2001;17A:660–663.Google Scholar
  124. 124.
    Roubenoff R. Sarcopenia: Effects on body composition and function. J Gerontol Med Sci 2003;58A:1012–1017.Google Scholar
  125. 125.
    McNally EM. Powerful gene—myostatin regulation of human muscle mass. N Engl J Med 2004;350:2642–2644.Google Scholar
  126. 126.
    Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol—Cell Physiology 2004;287:C834–C843.Google Scholar
  127. 127.
    Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. Brief report—Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682–2688.Google Scholar
  128. 128.
    Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486–1488.Google Scholar
  129. 129.
    Kotler DP. Cachexia. Ann Int Med 2000;133:622–634.Google Scholar
  130. 130.
    Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: A randomized controlled trial. J Gerontol Med Sci 2003;58:165–170.Google Scholar
  131. 131.
    Keller ET, Chang C, Ershler WB. Inhibition of NFKappaB activity through maintenance of IkappaB-alpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biological Chem 1996;271:26267–26275.Google Scholar
  132. 132.
    Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochemical Pharmacology 1983;32:1511-1518.Google Scholar
  133. 133.
    Lopez Ap, Figuls MR, Cuchi GU, Berenstein EG, Pasies BA, Alegre MB, Herdman M. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Sympt Mgt 2004;27:360–369.Google Scholar
  134. 134.
    Yeh SS, Wu SY, Le TP, Olson JS, Stevens MR, Dixon T, Procelli RJ, Schuster MW. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: Results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000;48:485-492.Google Scholar
  135. 135.
    Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: Literature review and review of our experience. J Nutr Hlth Aging 2002;6:191–200.Google Scholar
  136. 136.
    Yeh SS, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, Schuster MW. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol Med Sci 2001;56A:M48–M54.Google Scholar
  137. 137.
    Weisberg J, Wanger J, Olson J, Streit B, Fogarty C, Martin T, Casaburi R. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002;121:1070-1078.Google Scholar
  138. 138.
    Lambert CP, Sullivan DH, Evans WJ. Megestrol acetate-induced weight gain does not negatively affect blood lipids in elderly men: effects of resistance training and testosterone replacement. J Gerontol Med Sci 2003;58A:644–647.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • John E. Morley
    • 1
    • 2
    Email author
  • Moon Jong Kim
    • 1
  • Matthew T. Haren
    • 1
  1. 1.Division of Geriatric MedicineSaint Louis University School of Medicine and GRECC, VA Medical CenterSt. Louis
  2. 2.Division of Geriatric MedicineSaint Louis University School of MedicineSt. Louis

Personalised recommendations